<DOC>
	<DOC>NCT00741104</DOC>
	<brief_summary>This observational study will explore the Swedish national population of patients with rheumatoid arthritis (RA) on infliximab maintenance therapy in order to identify patients who may be eligible for a dose reduction study. Patients will be asked a variety of questions regarding their treatment dosing and disease activity, and then asked whether or not they would consider participating in a dose reduction study. Patients in this study will be described in terms of demographic and disease characteristics.</brief_summary>
	<brief_title>A Feasibility Study Exploring the Effect of Remicade on the Disease Activity in RA Patients (Study P05417)</brief_title>
	<detailed_description>Already known Subjects (RA and on at least 12 months ongoing Remicade treatment) from the clinic could participate if they are eligible.</detailed_description>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Rheumatoid arthritis, infliximab maintenance treatment for at least the past 12 months, given written informed consent. episodic treatment with infliximab</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>